A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 736-740

  Hokita, Shuichi ^a   Aikou, Takashi ^a   Miyazono, Futoshi ^a   Ishigami, Sumiya ^a   Aridome, Kuniaki ^a   Maenohara, Shigeho ^a   Saihara, Tetsushi ^a   Suenaga, Kuniaki ^a   Nomura, Hidehiro ^a   Maeda, Satoshi ^a   Takatori, Hiroyuki ^a   Arima, Hideo ^a   Uchikado, Yasuto ^a   Natsugoe, Shoji ^a   Takao, Sonshin ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Paclitaxel; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BODY TEMPERATURE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MEDICAL RECORD; MYALGIA; NEUTROPHILIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 33645730226     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0122-4     Document Type: Article

References (23)

1. Hasham-Jiwa N, Kasakura Y, Ajani JA (2002) Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol 7:219-224
2. Rowinsky EK, Cazenave LA, Donchower RC (1990) Taxol: a novel investigational anticrotubule agent. J Natl Cancer Inst 82:1247-1259
3. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, Chi CW (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14-18
4. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with untreated metastatic gastric carcinoma. Cancer J Sci Am 4:269-274
5. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi K (1996) Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74:704-710
6. Schipper DL, Wagener DJT (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7:137-149
7. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
8. Garcia AA, Parimoo D, Dimery I, Rogers M, Jeffers S, Muggia FM (1997) Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony stimulating factor on a biweekly schedule. Semin Oncol 24:S19-62-S19-66
9. Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, Ragaz J, Ayers D, Nakashima L, Rielly S, Dulude H (1998) A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Ann Oncol 9:1247-1249
10. Roth AD (2003) Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 14:175-177
11. Garcia AA, Leichmen CG, Lenz HJ (2001) Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 31:275-278
12. Cascinu S, Ficarelli R, Safi MAA, Graziano F, Catalano G, Cellerino R (1997) A phase I study of paclitaxel and 5-fluorourasil in advanced gastric cancer. Eur J Cancer 10:1699-1702
13. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
14. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
15. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 gastrointestinal cancer study group. Oncology 57:202-210
16. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
17. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group. Oncology 58:191-197
18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666
19. Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B (1996) Phase I study of paxlitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. Ann Oncol 7:311-313
20. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel - induced neuropathy. Ann Oncol 5:489-494
21. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D (1994) Phase I trial of 3-hour paclitaxel with or without granulocyte colony - stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248
22. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207-2212
23. Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Sugihara M, Ina K, Kusugami K, Goto S (2005) A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 25:1297-1301